Item 8.01 Other Events

As previously reported, on April 14, 2020, Adamis Pharmaceuticals Corporation (the "Company") received a letter from the Listing Qualifications Department of The NASDAQ Capital Market ("Nasdaq") notifying the Company that it has been granted an additional 180-day compliance period or until October 5, 2020, to regain compliance with the minimum $1.00 bid price per share requirement of Nasdaq's Marketplace Rule 5550(a)(2) (the "Rule"). On April 21, 2020, the Company received an additional notice from Nasdaq (the "Tolling Notice"), which stated that, due to current market conditions, Nasdaq has determined to toll the compliance period for the Rule through June 30, 2020. As a result, the new date by which the Company has to regain compliance with the Rule is December 21, 2020.

The Tolling Notice does not impact the Company's listing on The Nasdaq Capital Market at this time. To regain compliance, the closing bid price of the Company's common stock must be at least $1.00 per share for a minimum of 10 consecutive business days at any time prior to December 21, 2020.

© Edgar Online, source Glimpses